Application of azithromycin to anti-coronavirus infection

A coronavirus and azithromycin technology, applied in the field of medicine, can solve problems such as no reports on the anti-coronavirus activity of azithromycin

Active Publication Date: 2017-10-24
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After searching, there is no report on the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of azithromycin to anti-coronavirus infection
  • Application of azithromycin to anti-coronavirus infection
  • Application of azithromycin to anti-coronavirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1. Principle of Screening Model

[0040] The entry of coronavirus into the host cell is the first step in virus infection, and inhibiting the entry of the virus can effectively block the virus infection. The spike protein (Spike, S) on the surface of the coronavirus envelope is a key protein in the entry process of the coronavirus.

[0041] We applied the SARS-CoV envelope S gene (SARS-CoV S, Gene Bank: AY278741.1) and the MERS-CoV envelope S gene (MERS-CoV S, Gene Bank: JX869059.2) respectively. A plasmid expressing the S protein and the HIV core plasmid (pNL4-3-Luc-R) were co-transfected - E. - ), the SARS-CoV recombinant virus SARS-S / HIV [Ying Guo, Jennifer Tisoncik, Susanna McReynolds, Michael Farzan, Bellur S. Prabhabar, Thomas Gallagher, Lijun Rong and Michael Caffrey. New Region of SARS-CoV S Protein Critical for Viral Entry.Journal of Molecular Biology.2009,394:600-605.] and MERS-CoV recombinant virus MERS-S / HIV[Grehan K,Ferrara F,Temperton N.An optim...

Embodiment 2

[0042] Embodiment 2. Anti-SARS-CoV infection pharmacodynamics experimental method

[0043] The SARS coronavirus Urbani (Gene Bank: AY278741.1) strain is used in the present invention. Recombinant virus preparation [Ying Guo, Jennifer Tisoncik, Susanna McReynolds, Michael Farzan, Bellur S. Prabhabar, Thomas Gallagher, Lijun Rong and Michael Caffrey. Identification of a New Region of SARS-CoV S Protein Critical for Viral Entry. Journal of Molecular Biology.2009 ,394:600-605.]: Co-transfection of pcDNA3.1 / SARS-S plasmid and pNL4-3-Luc-R - E. - Put the plasmid into 293T cells, collect the supernatant 48 hours after transfection, and filter the supernatant through a 0.45 μm filter membrane. The supernatant contains SARS-S / HIV virus particles, and the recombinant virus can be used for infection. Prepare VSV-G / HIV recombinant virus in the same way.

[0044]Infection [Ying Guo, Jennifer Tisoncik, Susanna McReynolds, Michael Farzan, Bellur S. Prabhabar, Thomas Gallagher, Lijun Rong ...

Embodiment 3

[0047] Embodiment 3. Anti-MERS-CoV infection pharmacodynamics experimental method

[0048] Human betacoronavirus 2c EMC / 2012 (Gene Bank: JX869059.2) strain was used in the present invention. Recombinant virus preparation [Grehan K, Ferrara F, Temperton N.An optimized method for the production of MERS-CoV spike expressing viral pseudotypes.MethodsX.2015,2:379-384.]: Co-transfection of pCMV3 / MERS-S plasmid and pNL4- 3-Luc-R - E. - Put the plasmid into 293T cells, collect the supernatant 48 hours after transfection, and filter the supernatant through a 0.45 μm filter membrane. The supernatant contains MERS-S / HIV virus particles, and the recombinant virus can be used for infection.

[0049] Infection: The plasmid expressing human CD26 (Gene Bank: NM_001935.3) was transferred to 293T cells by the modified calcium phosphate method. The day before infection, press 6×10 per well 4 293T-CD26 cells were seeded on a 24-well plate at a density of 1 cell. The positive control compound...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of azithromycin to preparation of anti-coronavirus-infection medicine, and application of a medicine composition containing azithromycin to preparation of anti-coronavirus-infection medicine or combined application of azithromycin and other antiviral medicine.

Description

technical field [0001] The invention relates to the application of azithromycin in the preparation of anti-coronavirus infection drugs, and belongs to the field of medical technology. The present invention includes the single or combined application of azithromycin in the prevention or treatment of coronavirus. Background technique [0002] The virological classification of coronavirus (Coronavirus, CoV) belongs to the order Nidovirales, the family Coronaviridae, and the genus Coronavirinae. According to its evolution, coronavirus can be divided into α-coronavirus, β-coronavirus and γ-coronavirus [Gorbalenya AE, Enjuanes L, Ziebuhr J, et al. Nidovirales: evolving the largest RNA virus genome. Virus Res. 2006, 117:17-37.]( figure 1 ). [0003] Coronavirus is a spherical enveloped virus with a diameter of 50-200nm. Its genome is single-stranded positive-sense RNA, which encodes four structural proteins: spike protein (spike, S), membrane protein (membrane, M), envelope prot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7052A61P31/14
CPCA61K31/7052
Inventor 郭颖陈勍唐克
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap